Mobilized Peripheral Blood Mononuclear Cells, PLX, Frozen
Mobilized Human Peripheral Blood Mononuclear Cells (MNCs) are isolated from donors injected with 240μg/kg of Plerixafor® (aka Mozobil) the day before collection. Isolated MNCs are characterized by flow cytometry to ensure a highly enriched and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Since our founding in 2010, CGT Global has pursued our mission to transform healthcare as we accelerate cell and gene therapy research and clinical trials, streamline the commercialization of new treatments, and map the last mile to patient access to these life-changing remedies. By innovating each stage in the cycle; development, commercialization, and delivery, we reduce the overall cost of the care and multiply access points so that millions can receive cutting edge, life-saving gene and cell therapies.
Description
Mobilized Human Peripheral Blood Mononuclear Cells (MNCs) are isolated from donors injected with 240μg/kg of Plerixafor® (aka Mozobil) the day before collection. Isolated MNCs are characterized by flow cytometry to ensure a highly enriched and viable cell population.
Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.
Additional information
| Weight | N/A |
|---|---|
| Anticoagulant | |
| Format | |
| Grade | |
| Species | |
| Cell and Tissue Source | |
| Disease State | |
| Donor Attributes |
Product Information Sheet
Mobilized Mononuclear Cells, Plerixafor – Frozen
Material Safety Data Sheet
Mobilized Peripheral Blood
Selected publications demonstrating the use of mobilized peripheral blood and mobilized leukopak-derived CD34+ hematopoietic stem and progenitor cells in gene therapy, cell therapy, and transplantation workflows.
Hematopoietic reconstitution dynamics of mobilized peripheral blood-derived stem cells after gene therapy
Nature Communications · 2023
Mobilized peripheral blood-derived hematopoietic stem and progenitor cells were used for gene therapy, showing improved engraftment and recovery compared to traditional sources.
Mobilized Blood · HSPC · Gene Therapy
In vivo CRISPR gene editing in hematopoietic stem cells
Nature Biotechnology · 2022
Mobilized CD34+ hematopoietic stem cells were used in gene editing workflows to evaluate therapeutic genome engineering strategies.
CD34+ Cells · CRISPR · Gene Editing
Ex vivo expansion and functional characterization of hematopoietic stem cells
Stem Cell Research · 2023
Mobilized peripheral blood-derived hematopoietic stem cells were expanded ex vivo and evaluated for functional and therapeutic potential.
HSPC · Expansion · Stem Cell Biology
Optimized lentiviral production and transduction of primary human cells
Molecular Therapy Methods & Clinical Development · 2024
Mobilized CD34+ cells and primary immune cells were transduced using optimized viral production systems for gene and cell therapy applications.
CD34+ Cells · Viral Transduction
Improved workflows for gene modification in hematopoietic stem cells
Molecular Therapy Methods & Clinical Development · 2024
Mobilized hematopoietic stem cells were used to evaluate improved gene modification and cell engineering workflows.
Gene Editing · HSPC
Mobilized peripheral blood stem cells in transplantation and hematologic recovery
Blood · 2023
Mobilized peripheral blood stem cells were used in transplantation workflows to evaluate hematologic recovery and clinical outcomes.
Transplantation · Mobilized Blood




